MD NewslineDocetaxel Rechallenge vs. Cabazitaxel in Patients with Metastatic Castration-Resistant Prostate Cancer

ℹ️ Observational Association Only Evidence

Treatment sequencing after initial docetaxel in mCRPC remains heterogeneous in practice, particularly for patients who discontinue without progression. This retrospective analysis of 669 VA patients (407 cabazitaxel, 262 docetaxel rechallenge) from JAMA Network Open examined OS and secondary outcomes after second-line taxane therapy in this specific subgroup, applying inverse probability of treatment weighting to balance baseline characteristics including PSA, Gleason score, and prior therapy burden.

Clinical Considerations

• After weighting, docetaxel rechallenge was associated with improved OS compared with cabazitaxel (p=0.04) and longer time to subsequent systemic therapy or death in mCRPC patients who had not progressed on prior docetaxel
• Higher rates of ≥90% PSA reduction were observed with docetaxel rechallenge; subsequent systemic therapy use was broadly similar between arms
• Before weighting, rechallenge patients were older, more frail, and had more favorable disease features including lower PSA and fewer prior therapies, underscoring the selection pressures inherent in real-world treatment assignment
• Granulocyte colony-stimulating factor use was more frequent with cabazitaxel, consistent with its known toxicity profile and relevant to supportive care planning

Practice Applications

• Recognize docetaxel rechallenge as a hypothesis-generating viable option in carefully selected mCRPC patients who discontinued initial docetaxel without progression, pending prospective validation
• Interpret OS benefit in the context of short median follow-up (13.7 months) and a VA cohort that may not reflect broader mCRPC patient populations
• Consider patient frailty, prior docetaxel exposure depth, and intervening therapy burden when evaluating rechallenge eligibility; these factors drove baseline imbalance before statistical adjustment
• Monitor for prospective data comparing taxane sequencing strategies in mCRPC, where no randomized head-to-head evidence currently exists for this specific clinical scenario